Recommended
Recommended
More Related Content
What's hot
What's hot (14)
Similar to EVQLV Deck
Similar to EVQLV Deck (20)
Recently uploaded
Recently uploaded (20)
EVQLV Deck
- 1. An Artificial Intelligence Company Accelerating Biologic Therapies Confidential and Proprietary
- 2. EVQLV develops artificial intelligence engineered with life science data to accelerate how biologic therapies reach those in need AI-Powered Biologics Design Artificial Intelligence NLP/NLG Machine learning Probabilistic classifier Structural modeling Evolutionary model In silico screening Cloud computing Deep learning Biologics Monoclonal antibody Peptide Interferon Single domain antibody Interleukin Nanobody Fab CAR T Life Science NGS data Toxicity Receptor and pathway Molecular biology -Omics data Clinical trial data Crystal structure Confidential and Proprietary
- 3. Team Brett Averso Data Science, MSc Co-founder, CTO EVQLV is built with years of experience in machine learning, molecular biology, oncology, software engineering, agile development, structural biology, drug development, R&D partnerships, and computational biology. Sabyasachi Dash Biotechnology, PhD Life Science Advisor Jager Hartman Data Science, MSc Data Scientist Boris Shor Molecular Biology, PhD Research & Business Advisor Stuart Young Bioinformatics, PhD Data Architect Daniel Gigante Sales/Marketing Carsen Klock Software Engineer Aarshay Jain Data Science, MSc Data Scientist Shauna Soboh Operations Brett Spurrier Molecular Biophysics, PhD Structural Biologist Roland Dunbrack Biophysics, PhD SciTech Advisor Andrew Satz Data Science, MSc Co-founder, CEO Confidential and Proprietary Sarah Yam BioInformatics, MSc BioInformatics
- 4. Market $180 billion US biologics market 38% of US prescriptions are biologics Confidential and Proprietary
- 5. Challenge Biologic Failure Rates >90% 12-14 Years to FDA Approval of Biologics Confidential and Proprietary
- 6. Asset Transaction Values Pharmaceutical Value Chain Drug Discovery Pre- Clinical Phase I Clinical Trial Drug in Market Phase II Clinical Trial Phase III Clinical Trial At EVQLV, we use artificial intelligence to predict and reduce drug failure rates 73% Fail 31% Fail 36% Fail 56% Fail 30% Fail $105M $55M $140M $75M$105M $40M Discovery & Development Phase Drug Failure Rates Confidential and Proprietary
- 7. Current Drug Discovery & Development Model Pre-clinicalDrug Design EVQLV Drug Design <1 year | <$10 Million Computational Design and Optimization 4-5 years | $674 Million In-vitro Discovery EVQLV Value Proposition Money Saved Time Saved >$500 Million 3-4 Yrs Current Process Length: 12-14 Yrs Cost: $2.6B Confidential and Proprietary Pre-clinicalOptimizationValidationDiscovery
- 8. Business Models Scalable fee-based model through contracts generated by partner organizations Contract Research Partnerships Pharmaceutical Collaborations Direct fee-based model, mixed with success-based milestone payments and royalties Licensable Assets Scalable and repeatable fee, milestone, and royalty based model Confidential and Proprietary
- 9. Projected Annual Revenue $20,000,000 $0 2020 2021 2022 2023 2024 $80,000,000 $60,000,000 $40,000,000 $43.6M $75.6M Total Revenue Net Income Total Expenses Confidential and Proprietary $24.8M $9.3M $600K 70 Collabs 110 Collabs 46 Collabs 24 Collabs 11 Collabs
- 10. Accomplishments Since January 2020 Product Business Development 2 research collaborations 7 LOIs being converted into contracts 13 deals in negotiation Computationally validated algorithms; laboratory results further validated efficacy of our algorithm Team In less than 6 months, grew from two founders to 10 team members, including eight technologists Confidential and Proprietary
- 11. EVQLV Incorporation Complete AI + Ab Design Validation AI+Antibody Design Complete Sep ‘19 Dec ‘19Complete Roadmap Jan ‘20 Predictive Toxicity and Targeting ✓ InitiateMar ‘20 Initiated Partnership Campaign Feb ‘20 AI+Biological Function InitiateSep ‘20 AI+De Novo Antibody Design CompleteDec ‘20 AI+Target Discovery InitiateJan ‘21 AI+Clinical Trial Design InitiateJun ‘21 July ‘21 AI+Humanize & AI+Patentability CompleteDec ‘19 Initiate Expand to Add’l Biologics Jan ‘21 Initiate Jan ‘22 Initiate Dec ‘21 Initiate In Vitro Studies In Vivo Studies AI+Lab Automation ✓ ✓✓ ✓ ✓ Confidential and Proprietary
- 12. info@evqlv.com www.evqlv.com New York, NY Using Artificial Intelligence to Accelerate the Speed at Which Healing Reaches Those in Need